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Abstract
Objective
To characterize hepatitis C virus (HCV) epidemiology in countries of the Fertile Crescent
region of the Middle East and North Africa (MENA), namely Iraq, Jordan, Lebanon, Pales-
tine, and Syria.
Methods
We systematically reviewed and synthesized available records of HCV incidence and prev-
alence following PRISMA guidelines. Meta-analyses were implemented using a DerSimo-
nian-Laird random effects model with inverse weighting to estimate the country-specific
HCV prevalence among the various at risk population groups.
Results
We identified eight HCV incidence and 240 HCV prevalence measures in the Fertile
Crescent. HCV sero-conversion risk among hemodialysis patients was 9.2% in Jordan and
40.3% in Iraq, and ranged between 0% and 3.5% among other populations in Iraq over dif-
ferent follow-up times. Our meta-analyses estimated HCV prevalence among the general
population at 0.2% in Iraq (range: 0–7.2%; 95% CI: 0.1–0.3%), 0.3% in Jordan (range:
0–2.0%; 95% CI: 0.1–0.5%), 0.2% in Lebanon (range: 0–3.4%; 95% CI: 0.1–0.3%), 0.2% in
Palestine (range: 0–9.0%; 95% CI: 0.2–0.3%), and 0.4% in Syria (range: 0.3–0.9%; 95% CI:
0.4–0.5%). Among populations at high risk, HCV prevalence was estimated at 19.5% in Iraq
(range: 0–67.3%; 95% CI: 14.9–24.5%), 37.0% in Jordan (range: 21–59.5%; 95% CI: 29.3–
45.0%), 14.5% in Lebanon (range: 0–52.8%; 95% CI: 5.6–26.5%), and 47.4% in Syria
(range: 21.0–75.0%; 95% CI: 32.5–62.5%). Genotypes 4 and 1 appear to be the dominant
circulating strains.
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Conclusions
HCV prevalence in the population at large appears to be below 1%, lower than that in other
MENA sub-regions, and tending towards the lower end of the global range. However, there
is evidence for ongoing HCV transmission within medical facilities and among people who
inject drugs (PWID). Migration dynamics appear to have played a role in determining the cir-
culating genotypes. HCV prevention efforts should be targeted, and focus on infection con-
trol in clinical settings and harm reduction among PWID.
Introduction
Hepatitis C virus (HCV) is a main risk factor for liver cancer and cirrhosis and is estimated to
affect 1–3% of the population in most countries globally [1, 2]. The vast majority of HCV
transmission is blood-borne and largely preventable [3, 4]. Recent breakthroughs in HCV
treatment research suggest promising prospects for treating and containing the infection, and
raise hope for an improved quality of life among infected individuals [5].
In few countries of the Middle East and North Africa (MENA) region, namely Egypt and
Pakistan, HCV is prevalent at high levels: 14.7% in Egypt [6, 7] and 4.8% in Pakistan [8, 9].
Meanwhile, infection levels remain poorly estimated for most MENA countries including
those in the Fertile Crescent (FC). Geographically, for this study, we define the FC subregion of
MENA to include Iraq, Jordan, Lebanon, Palestine, and Syria. Since Egypt was covered by a
separate systematic review published recently [7], we did not include Egypt as part of our
study. FC countries share historical, socio-cultural, and geo-political similarities, and their
health care systems are often directly or indirectly interlinked or affected by decades of political
turmoil and refugee waves within this territory.
Our study primarily aims at characterizing HCV epidemiology in these countries by 1)
systematically reviewing and synthesizing all available published and unpublished records of
HCV incidence and prevalence among the different population groups, and 2) estimating the
population-level country-specific HCV prevalence by pooling available HCV prevalence mea-
sures among the general population in each country. A secondary outcome of our study is
an analysis of HCV genotype diversity. This work is conducted under the umbrella of the
MENA HCV Epidemiology Synthesis Project; an ongoing effort to characterize HCV epidemi-
ology and inform key public health research, policy, and programming priorities in MENA [7,
10–15].
Materials and Methods
Data sources and search strategy
We systematically reviewed all HCV incidence (Table 1) and prevalence (Tables 2 and 3 and
S2 Table) data in FC following the Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) guidelines [16]. The PRISMA checklist can be found in S1 Fig. The
methodology was adapted from a recently published protocol for a systematic review of HCV
incidence and prevalence measures for countries in the Horn of Africa subregion of MENA
[10, 17]. Our search criteria can be found in S2 Fig. Briefly, we surveyed PubMed and Embase
(up to April 23, 2015), different regional databases (up to November 5–16, 2014), the abstract
archives of the International AIDS Society conferences (up to November 16, 2014), and coun-
try-level and international organizations’ reports available through the MENA HIV/AIDS
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Epidemiology Synthesis Project database (up to April 23, 2015) [18, 19]. We used a broad
search criteria with no language restrictions. PubMed and Embase were searched using text
terms and MeSH/Emtree terms exploded to cover all subheadings. Our search was restricted to
articles published after 1989, the year when HCV was first discovered [20, 21].
Study selection
The search results were imported into a reference manager, Endnote, where duplicate publica-
tions were identified and excluded. The titles and abstracts of remaining records were screened
for relevance, and full-texts of articles deemed relevant or potentially relevant were retrieved
for further screening. The references of all articles and all reviews of literature were also
checked to identify additional articles that could have been potentially missed. Any document
reporting a measure of HCV incidence and/or prevalence based on primary data was consid-
ered for the review (Fig 1). Case reports, case series, editorials, letters to editors, commentaries,
studies referring to hepatitis C as non-A non-B hepatitis, and records of HCV among military
personnel who were stationed in this region for some time, but are from countries outside the
region, were excluded from our review. A secondary independent screening for articles report-
ing HCV genotype information, irrespective of their inclusion of HCV incidence and/or preva-
lence measures, was also performed (S3 Fig).
In this work, a “report” refers to a document containing outcome measures of interest,
while a “study” refers to all details pertaining to a specific outcome measure. Accordingly, one
report could contribute multiple studies, and multiple reports of the same study, after being
identified as duplicates, are considered as one study.
Table 1. Studies reporting hepatitis C virus (HCV) incidence in countries of the Fertile Crescent.
First author,
year of
publication
[citation]
Year of
data
collection
Study
site
Population’s
classiﬁcation
based on risk of
HCV exposure
Population Sample size
at
recruitment
Lost to
follow-
up
HCV sero-
conversion risk
(relative to total
sample size)
Duration
of follow-
up
Jordan
Batieha, 07 [39] 2003 Dialysis
units/
National
High risk population Hemodialysis patients 1300 9.2% 12 months
Iraq
Al-Rubaie, 11
[40]
2009 Hospital High risk population Hemodialysis patients 57 0 40.3% 12 months
Al-Jadiry, 08
[42]
2007 Hospital Special clinical
population
Pediatric patients with
acute lymphoblastic
leukemia
123 0 3.2% 30 months
(median)
Al-Kubaisy, 00
[44]
Hospital High risk population Newborns to HCV
infected women
26 0 0% 6 months
Al-Ali, 14 [41] 2006–07 Hospital Special clinical
population
Pediatric cancer
patients on
chemotherapy
85 22 3.2% 12 months
Al-Ani, 11 [43] 2007–09 Hospital Low risk population Healthy children 60 0 0% 6 months
Al-Ani, 11 [43] 2007–09 Hospital Special clinical
population
Pediatric patients with
leukemia on
chemotherapy
29 0 3.5% 6 months
Al-Ani, 11 [43] 2007–09 Hospital Special clinical
population
Pediatric patients with
leukemia who have
had their baseline
screening prior to
chemotherapy
27 0 0% 6 months
doi:10.1371/journal.pone.0135281.t001
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Table 2. Studies reporting hepatitis C virus (HCV) prevalence among populations at high risk in countries of the Fertile Crescent.
First author, year of
publication [citation]
Years of
data
collection
Study site Study sampling
procedure
Population Sample
size*
HCV
prev**
Iraq (n = 36)
Abdul-Aziz, 01 [46] 1999–01 Central laboratory Convenience Hemodialysis patients 95 0%
Abdul-Aziz, 01 [46] 1999–01 Central laboratory Convenience Thalassemic patients 163 8%
Abdul-Karim, 11 [149] 2008 Hospital Convenience Patients with bleeding disorders 243 40.3%
Abdullah, 12 [48] 2010 Hemodialysis centers Convenience Hemodialysis patients 236 39%
Abdullah, 12 [47] 2005–07 Dialysis unit Convenience Hemodialysis patients 80 28.7%
Abed, 10 [150] 2008 Thalassemia center Convenience Thalassemic patients 111 46%
Albahadle, 13 [151] 2011 Thalassemia center Convenience Thalassemic patients (0–18 years) 206 19.9%
Al-Barzinji, 06 [152] 2004 Hospital Convenience Multi-transfused leukemia patients
on chemotherapy (1–12 years)
88 4.5%
Al-Beldawi, 10 [56] 2006 Hemophilia center Convenience Hemophilia patients (<20 years) 200 40%
Al-Dulaimi, 12 [49] 2010–11 Hospital Convenience Hemodialysis patients 84 14.3%
Al-Greti, 13 [153] 2011–12 Thalassemia center Convenience Thalassemic patients 100 37%
Al-Juboori, 12 [154] 2010–11 Thalassemia center Convenience Thalassemic patients (<20 years) 50 10%
Al Kubaisy, 06 [45] 1998 Hospital SRS Thalassemic patients (2–10 years) 559 67.3%
Al-Marzoqi, 09 [66] 2008 Thalassemia center Convenience Thalassemic patients (children) 50 38%
Al-Mashhadani, 07 [50] 2002 Hospital Convenience Hemodialysis patients 87 11.5%
Al-Thwani, 06 [57] 1997–04 Blood trans center Convenience Hemophilia patients 100 25%
Al Wtaify, 00 [155] 1998–99 Thalassemia center Convenience Thalassemic patients (children) 200 9.5%
Al-Zamili, 09 [156] 2007–08 Hospital Convenience Thalassemic patients (<20 years) 325 4%
Easa, 09 [157] 2007–08 Thalassemia center Convenience Thalassemic patients (5–18 years) 140 26.4%
Fadhil, 12 [158] 2010–11 Thalassemia center Convenience Thalassemic patients 200 21%
Hashem, 13 [159] 2011 Hereditary blood
diseases center
Convenience Thalassemic patients 284 19%
Hassan, 08 [137] 1996–01 Central laboratory Convenience Thalassemic patients 136 16.9%
Khaled, 14 [160] 2012 Thalassemia center Convenience Thalassemic patients 480 10.4%
Khalid, 12 [161] Thalassemia center Convenience Thalassemic patients 200 17.5%
Khattab, 08 [51] 2003–05 Renal transplant
center
Convenience Hemodialysis patients 169 7.1%
Khattab, 10 [52] 2003–08 Renal transplant
center
Convenience Hemodialysis patients 244 4.9%
Mnuti, 11 [53] 2008–10 Hemodialysis unit Convenience Hemodialysis patients 100 41%
Muhsin, 13 [58] 2011–12 Hospital SRS Hemophilia patients 60 6.7%
Muhsin, 13 [58] 2011–12 Hospital SRS Thalassemic patients 56 25%
Mustafa, 10 [162] 2003–04 Thalassemia center Convenience Thalassemic patients (<20 years) 626 28.1%
Omer, 11 [163] 2006–08 Hospital Convenience Multi-transfused leukemia patients 291 3.4%
Omer, 11 [164] 2010 Thalassemia center Convenience Thalassemic patients 54 7.4%
Raham, 11 [165] 1999–00 Thalassemia center Convenience Thalassemic patients 110 26.4%
Ramzi, 10 [54] 2009 Dialysis center Convenience Hemodialysis patients 101 26.7%
Saadoon, 12 [64] Blood trans center Convenience Thalassemic patients 162 34.6%
Shihab, 14 [55] 2012–13 Hospital Convenience Hemodialysis patients 122 42.6%
Jordan (n = 7)
Al-Jamal, 09 [166] 2007–08 Hospitals Convenience Hemodialysis patients 120 28%
Al-Sweedan, 11 [68] 2008 Thalassemia unit Convenience Thalassemic patients 122 32.8%
Batchoun, 11 [167] Hospitals Convenience Hemodialysis patients 134 47.7%
Batieha, 07 [39] 2003 Hemodialysis units Convenience Hemodialysis patients 1711 21%
(Continued)
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Data extraction and data synthesis
Data from relevant reports were extracted by HC. To check for consistency, 10% of the reports
were double extracted by another co-author (KC). The list of extracted information can be
found in S1 Table. The extracted data were then synthesized by country and by populations’
risk of acquiring HCV (high, intermediate, and low risk). Our classification of risk was
informed by HCV epidemiology literature [2, 22, 23] and a previously published classification
[12]. In events where the level of exposure to HCV in certain populations was uncertain, and
hence difficult to classify within the three pre-determined levels of risk, we followed a conserva-
tive approach that grouped such populations into a distinct risk category. We labeled this
category as ‘special clinical populations’ since all of these populations were clinical populations.
Details pertaining to the definitions and risk classification of identified populations can be
found in S4 Fig.
The quality of HCV incidence and prevalence measures identified through our review was
determined by assessing the risk of bias (ROB) for each study using the Cochrane approach
Table 2. (Continued)
First author, year of
publication [citation]
Years of
data
collection
Study site Study sampling
procedure
Population Sample
size*
HCV
prev**
Bdour, 02 [111] Hemodialysis units Convenience Hemodialysis patients 283 32.5%
Ghunaimat, 07 [168] Hemodialysis unit Convenience Hemodialysis patients 209 49.8%
Said, 95 [169] 1994 Hemodialysis centers Convenience Hemodialysis patients 273 24.5%
Lebanon (n = 6)
Abdelnour, 97 [72] Hospitals Convenience Hemodialysis patients 108 16%
Inati, 09 [74] Thalassemia center SRS Thalassemic patients 200 0%
Mahfoud, 10 [71] 2007–08 Not applicable RDS People who inject drugs 106 52.8%
Naman, 96 [73] Hemodialysis centers Convenience Hemodialysis patients 317 27%
Ramia, 02 [75] 1999–00 Thalassemia center Convenience Thalassemic patients 395 14.0%
Ramia, 03 [76] Hospital Convenience Multi-transfused cancer patients 65 4.6%
Palestine (n = 3)
Dumaidi, 14 [87] 2012–
13
Hemodialysis units Convenience Hemodialysis patients 146 27.4%
El-Kader, 10 [88] 2007 Hospital Convenience Hemodialysis patients 246 17.9%
Stulhofer, 12 [89] 2010 Different localities RDS People who inject drugs 199 45.2%
Syria (n = 5)
Abdulkarim, 98 [92] Dialysis unit Convenience Hemodialysis patients 120 75%
Ali, 12 [96] 2007–
11
Hospital Convenience Hemophilia patients 375 20.5%
Syrian MOH, 08 [95] 2006 Not applicable Snowball Drug users including people who
inject drugs
336 21%
Moukeh, 09 [93] 2006 Hospital Convenience Hemodialysis patients 550 54.4%
Othman, 01 [170] 1996 Hospital Convenience Hemodialysis patients 139 48.9%
MENA HIV/AIDS ESP, Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project database; MOH, Ministry of Health; Prev, prevalence;
RDS, respondent driven sampling; SRS, simple random sampling; Trans, transfusion.
*The table reports only studies whose sample size is greater or equal to 50 participants. For space considerations, the table shows the overall HCV
measure of each study rather than stratiﬁcations within population subgroups.
**The decimal places of the prevalence ﬁgures are as reported in the original report, but prevalence ﬁgures with more than one decimal places were
rounded to one decimal place.
doi:10.1371/journal.pone.0135281.t002
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Table 3. Studies reporting hepatitis C virus (HCV) prevalence among the general population (populations at low risk) in countries of the Fertile
Crescent.
First author, year of
publication [citation]
Years of data
collection
Study site Study sampling
procedure
Population Sample
size*
HCV
prev**
Iraq (n = 45)
Abdul-Aziz, 01 [46] 1999–01 Central laboratory Convenience Blood donors 20108 0.8%
Abdul-Aziz, 01 [46] 1999–01 Central laboratory Convenience New employees 257 0.4%
Abdullah, 12 [47] 2005–07 Convenience Blood donors 100 1%
Al-Ani, 11 [43] 2007–09 Hospital Convenience Children 60 0%
Al-Azzawi, 06 [171] 2004 Primary health
centers
Convenience Pregnant women 100 1%
Al-Doori, 06 [172] 2004–05 Central laboratory Convenience Blood donors 1978 0.4%
Al-Duliami, 12 [173] 2010–11 Central laboratory SRS Blood donors 90 0%
Al-Greti, 13 [153] 2011–12 Convenience General population 50 4%
Al-Hamdani, 12 [174] 2003–04, 06, 08–
09
Hospital Convenience New employees 4162 2.6%
Ali, 09 [175] 2007–08 Blood bank Convenience Blood donors 600 1.7%
Al-Jebori, 10 [176] 2003–09 Central laboratory Convenience Mixed general population 120460 0.2%
Aljooani, 12 [177] 2005–07 Hospital Convenience Blood donors 430 2.8%
Al-Juboury, 10 [178] 2007–08 Blood bank Convenience Blood donors 23336 0.5%
Al-Kamil, 11 [179] 2006–08 Central blood bank Convenience Blood donors 161987 0.1%
Al-Kubaisy, 02 [102] Hospitals & health
care centers
SRS Pregnant women 3491 3.2%
Al-Saad, 09 [61] 2008 Hospital Convenience General population 100 0%
Al Wtaify, 00 [155] 1998–99 Hospital SRS Outpatient hospital
attendees (children)
200 0.5%
Al-Zamili, 09 [156] 2007–08 Hospital Convenience Children 325 0%
Amin, 12 [180] 2008–09 Blood bank Convenience Blood donors 35540 0.1%
Ataallah, 11 [181] 2006–09 National blood trans
center
Convenience Blood donors 495648 0.3%
Chiad, 09 [182] 2003–04 National blood trans
center
Convenience Blood donors 1000 1%
Chironna, 03 [105] Refugee camp Convenience Refugees 637 0.1%
Fadhil, 12 [158] 2010–11 Hospital Convenience Outpatient hospital
attendees
50 0%
Fawzi, 11 [183] 2010 Hospital & health
centers
Convenience Pregnant women 520 1.1%
Hamim, 12 [184] 2006–10 Main blood trans
center
Convenience Outpatient hospital
attendees
4886 0.9%
Hamim, 12 [185] 2008–09 Blood trans centers Convenience Blood donors 871973 0.4%
Hassan, 08 [137] 1996–01 Central laboratory Convenience Blood donors 42140 0.1%
Hussain, 08 [186] 2004–05 Hospital Convenience General population 108 0%
Hussein, 10 [187] 2006–07 Central blood bank Convenience Blood donors 31574 0.1%
Hussain, 10 [188] 2008–09 Convenience Blood donors 117 0.8%
Jassim, 11 [189] Convenience Blood donors 170 0%
Khalid, 12 [161] Central blood bank Convenience Blood donors 100 2%
Naji, 13 [190] 2011–12 Central laboratory Convenience Newly married individuals 200 1.5%
Noaman, 12 [63] 2009–10 Blood bank Convenience Blood donors 93 1.1%
Obied, 14 [100] 2012–13 Central blood bank Convenience Blood donors 5179 0.4%
Omer, 11 [163] 2006–08 Hospital Convenience General population 350 0.3%
Richter, 14 [191] 2011 Community Convenience First generation
immigrants
290 0.3%
(Continued)
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Table 3. (Continued)
First author, year of
publication [citation]
Years of data
collection
Study site Study sampling
procedure
Population Sample
size*
HCV
prev**
Saadoon, 08 [192] 2007 Hospitals Convenience Pregnant women 875 5.1%
Saadoon, 12 [64] Blood bank Convenience Blood donors 1128 0.6%
Salih, 07 [193] 2007 Hospital Convenience Blood donors 95 2.1%
Salman, 07 [194] 2006–07 Antenatal clinics Convenience Pregnant women 60 0%
Tarky, 13 [59] 2005–06 Households StRS General population 9610 0.4%
Tawfeeq, 13 [101] 2011–12 Blood bank Convenience Blood donors 15560 0.3%
Tofﬁk, 06 [195] Hospital Convenience Outpatient clinic
attendees
100 0%
Tofﬁk, 06 [195] Convenience Blood donors 200 0.5%
Jordan (n = 5)
Al Abbadi, 14 [196] 2009–11 Blood bank Convenience Blood donors 94270 0.1%
Al-Gani, 11 [197] 2006–09 Blood bank Convenience Blood donors 8190 0.9%
Hamoudi, 13 [112] Health centers SRS Health centers’ attendees 706 0.4%
Jbara, 06 [198] 2003–05 Blood bank Convenience Blood donors 8750 0.8%
Rashdan, 08 [103] 2004–06 Blood bank Convenience Blood donors 14236 0.2%
Lebanon (n = 13)
Araj, 95 [77] SRS Blood donors 4179 0.1%
Baddoura, 02 [84] Laboratories (nation-
wide)
Convenience General population
(Lebanese)
2879 0.6%
Baddoura, 02 [84] Laboratories (nation-
wide)
Convenience General population
(immigrants)
103 2.9%
Irani-Hakime, 01 [199] 1999 Blood bank Convenience Blood donors 600 0.2%
Irani-Hakime, 06 [78] 1997–03 Blood bank Convenience Blood donors 16084 0.4%
Nabulsi, 97 [80] 1993–95 Antenatal clinics Pregnant women 558 0%
Naman, 96 [73] Blood donors 7771 0.4%
Ramia, 03 [76] Hospital SRS Blood donors 500 0.2%
Ramia, 05 [81] 2002–03 Blood bank SRS Blood donors 56 0%
Salem, 03 [82] Hospital SRS Outpatient hospital
attendees
70 0%
Salem, 03 [82] Hospital SRS Blood donors 150 0%
Tamim, 01 [83] 1998–00 Blood bank Convenience Blood donors (Lebanese) 5027 0.3%
Tamim, 01 [83] 1998–00 Blood bank Convenience Blood donors (non-
Lebanese)
88 3.4%
Palestine (n = 11)
PHIC, 14 [33] 2013 Blood banks
(hospitals)
Blood donors 19571 0.2%
PHIC, 14 [33] 2013 National blood bank Blood donors 9643 0.3%
MENA HIV ESP, 11 [18, 32] 2011 Blood donors 63477 0.2%
PHIC, 10 [34] 2009 Blood banks
(hospitals)
Blood donors 48001 0.2%
PHIC, 08 [35] 2007 Blood banks
(hospitals)
Blood donors 49105 0.3%
PHIC, 07 [36] 2006 Blood donors 53151 0.2%
PHIC, 06 [37] 2005 Blood bank Blood donors 45029 0.2%
PHIC, 04 [38] 2003 Blood bank Blood donors 44990 0.3%
Novack, 07 [91] 1999–02 Blood bank Convenience Blood donors 2784 3.9%
Shemer-Avni, 98 [90] Blood bank Convenience Blood donors 1509 2.2%
(Continued)
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[24], and by evaluating the precision of the reported measures. A description of the quality
assessment criteria and studies’ ROB appraisal can be found in S5 Fig.
Quantitative analysis
For each country, HCV antibody and RNA prevalence data in studies comprising at least 50
participants were stratified by population risk and summarized using reported ranges (Tables 2
and 3, and S2 and S3 Tables). Meta-analyses of HCV prevalence measures were conducted, for
each country, for the various populations at risk whenever at least five HCV measures were
available. Studies comprising a minimum of 25 participants were considered eligible for inclu-
sion in the meta-analysis. HCV prevalence for the total sample was replaced with stratified
measures whenever the sample size requirement was fulfilled at the level of each stratum. For
each study, one final stratification was considered based on a pre-defined sequential order that
prioritizes nationality followed by population, sex, year, region, and age.
The variance of the prevalence measures was stabilized using the Freeman-Tukey type arc-
sine square-root transformation [25]. Estimates for HCV prevalence were weighed using the
inverse variance method and then pooled using a DerSimonian-Laird random effects model
[26]. This model assumes a normal distribution of true effect sizes across studies, and therefore
accounts for the sampling variation as well as the heterogeneity in effect size [27]. Heterogene-
ity measures were also calculated (Table 4) [27, 28].
For each country, we calculated the frequency of occurrence of each genotype relative to all
identified genotypes (Table 5). Here, individuals testing positive for multiple genotypes con-
tributed separately to the quantification of each of the identified genotypes. Shannon Diversity
Index [29] was applied to the resulting distributions to assess the diversity of genotypes across
Table 3. (Continued)
First author, year of
publication [citation]
Years of data
collection
Study site Study sampling
procedure
Population Sample
size*
HCV
prev**
Shemer-Avni, 98 [90] Hospital SRS Outpatient hospital
attendees
124 9%
Syria (n = 10)
Ali, 10 [200] 2000–07 Blood trans center Convenience Blood donors 131403 0.4%
MENA HIV ESP, 10 [18, 32] Q 1, 2006 Blood donors 55549 0.3%
MENA HIV ESP, 10 [18, 32] Q 2, 2006 Blood donors 87920 0.4%
MENA HIV ESP, 10 [18, 32] Q 3, 2006 Blood donors 77734 0.6%
MENA HIV ESP, 10 [18, 32] Q 4, 2006 Blood donors 83347 0.5%
MENA HIV ESP, 10 [18, 32] Q 1, 2007 Blood donors 83501 0.4%
MENA HIV ESP, 10 [18, 32] Q 2, 2007 Blood donors 92452 0.4%
MENA HIV ESP, 10 [18, 32] Q 3, 2007 Blood donors 83560 0.5%
MENA HIV ESP, 10 [18, 32] 2011 Blood donors 416984 0.6%
Othman, 02 [97] Convenience Blood donors 2100 0.9%
MENA HIV ESP, Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project database; PHIC, Palestinian Health Information Center; Prev,
prevalence; Q, quarter; RDS, respondent driven sampling; SRS, simple random sampling; StRS, stratiﬁed random sampling; Trans, transfusion.
*The table reports only studies whose sample size is greater or equal to 50 participants. For space considerations, the table shows the overall HCV
measure of each study rather than stratiﬁcations within population subgroups.
**The decimal places of the prevalence ﬁgures are as reported in the original report, but prevalence ﬁgures with more than one decimal places were
rounded to one decimal place.
doi:10.1371/journal.pone.0135281.t003
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Fig 1. Flow chart of article selection for the systematic review of hepatitis C virus (HCV) incidence and prevalence in the Fertile Crescent
countries, adapted from the PRISMA 2009 guidelines [16].
doi:10.1371/journal.pone.0135281.g001
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Table 4. Pooled mean estimates for hepatitis C virus (HCV) prevalence stratified by populations’ risk of infection across countries of the Fertile
Crescent.
Studies Samples Prevalence Effect size Heterogeneity measures
Total N Total N Range (%) Mean
(%)
95% CI Q (p-value)* τ2** I2 (conﬁdence
limits)†
Prediction
interval (%)‡
Iraq
General population 99 1859563 0.0–7.2 0.2 0.1–0.3 2355.9
(p<0.0001)
0.0014 95.8% (95.3–
96.3%)
0.0–0.8
Populations at high risk 58 6707 0.0–67.3 19.5 14.9–
24.5
1345.8
(p<0.0001)
0.1982 95.8% (95.1–
96.4%)
0.0–62.8
Populations at
intermediate risk
28 8398 0.0–35.1 1.5 0.7–2.5 205.2
(p<0.0001)
0.0227 86.8% (82.1–
90.3%)
0.0–8.2
Special clinical
populations
45 18845 0.0–76.2 5.0 3.4–6.9 1146.5
(p<0.0001)
0.0631 96.2% (95.5–
96.7%)
0.0–22.1
Jordan
General population 12 126152 0.0–2.0 0.3 0.1–0.5 170.7
(p<0.0001)
0.0016 93.6% (90.5–
95.6%)
0.0–1.1
Populations at high risk 12 2888 21.0–59.5 37.0 29.3–
45.0
137.8
(p<0.0001)
0.07 92.0% (87.9–
94.7%)
11.1–67.7
Populations at
intermediate risk
1 152 0.65
Special clinical
populations
1 143 40.5
Mixed populations 1 426 4.5
Lebanon
General population 16 38059 0.0–3.4 0.2 0.1–0.3 38.2
(p<0.0008)
0.0008 60.8% (32.3–
77.3%)
0.0–0.7
Populations at high risk 10 1309 0.0–52.8 14.5 5.6–
26.5
223 (p<0.0001) 0.2011 96.0% (94.2–
97.2%)
0.0–66.0
Populations at
intermediate risk
7 1050 0.0–7.7 1.2 0.1–3.3 24.9
(p<0.0003)
0.0224 76.0% (49.3–
88.6%)
0.0–10.7
Special clinical
populations
4 312 0.0–19.6
Palestine
General population 53 337384 0.0–9.0 0.2 0.2–0.3 637.8
(p<0.0001)
0.0019 91.8% (90.1–
93.3%)
0.0–0.9
Populations at high risk 4 584 6.8–45.2
Populations at
intermediate risk
0
Special clinical
populations
0
Mixed populations 12 53363 0.3–4.9
Syria
General population 17 1114550 0.3–0.9 0.4 0.4–0.5 216.6
(p<0.0001)
0.0002 92.6% (89.7–
94.7%)
0.3–0.7
Populations at high risk 8 1279 21.0–75.0 47.4 32.5–
62.5
190.6
(p<0.0001)
0.1779 96.3% (94.5–
97.6%)
3.8–93.8
Populations at
intermediate risk
4 725 2.0–5.8
Special clinical
populations
2 218 1.0–48.0
All countries
General population 197 3475708 0.0–9.0 0.2 0.2–0.3 4497.5
(p<0.0001)
0.0013 95.6% (95.3–
96.0%)
0.0–0.8
(Continued)
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countries, with a higher score indicating more diversity (Table 5). The country-specific distri-
butions of HCV genotypes among HCV RNA positive individuals were also described (S6 Fig).
Analyses were performed using SPSS 22.0 [30] and R 3.1.2. [31].
Results
Search results
Fig 1 describes the process of study selection based on PRISMA guidelines [16]. We identified
a total of 465 citations (92 through PubMed, 153 through Embase, and 220 through regional
databases). A total of 166 records were identified as relevant or potentially relevant after
removing duplicates and screening the titles and abstracts of remaining records. Out of these,
115 records were eligible for inclusion in the systematic review during the full-text screening
stage. Twenty additional records were identified through screening the bibliographies of stud-
ies and reviews. Twenty one HCV prevalence measures from country-level data were also iden-
tified through the MENA HIV/AIDS Epidemiology Synthesis Project database [18, 32–38]. To
sum, a total of 135 eligible reports and 21 HCV prevalence measures from county-level data
Table 4. (Continued)
Studies Samples Prevalence Effect size Heterogeneity measures
Total N Total N Range (%) Mean
(%)
95% CI Q (p-value)* τ2** I2 (conﬁdence
limits)†
Prediction
interval (%)‡
Populations at high risk 92 12767 0.0–75.0 23.6 19.8–
27.5
2273.6
(p<0.0001)
0.1762 96.0% (95.5–
96.4%)
0.3–64.5
Populations at
intermediate risk
40 10325 0.0–35.2 1.5 0.9–2.3 243.5
(p<0.0001)
0.0208 84.0% (79.0–
87.8%)
0.0–7.7
Special clinical
populations
52 19518 0.0–76.2 5.4 3.7–7.4 1377.9
(p<0.0001)
0.0729 96.3% (95.7–
96.8%)
0.0–24.4
Mixed populations 13 53789 0.3–4.9
*Q: the Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size.
**τ2: the estimated between-study variance in the double arcsine transformed proportions of the true effect sizes. The back-transformed τ2 was not
calculated as the methodology to do so is not currently available.
†I2: a measure assessing the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.
‡Prediction interval: estimates the 95% interval in which the true effect size in a new HCV study will lie.
doi:10.1371/journal.pone.0135281.t004
Table 5. Frequency, distribution and Shannon Diversity Index of identified hepatitis C virus (HCV) genotypes across countries of the Fertile
Crescent.
Country Iraq Jordan Lebanon Palestine Syria
n (%) n (%) n (%) n (%) n (%)
Genotype 1 212 (33.2%) 30 (42.3%) 134 (39.9%) 38 (28.6%) 199 (29.5%)
Genotype 2 3 (0.5%) 53 (15.8%) 1 (0.8%) 5 (0.7%)
Genotype 3 24 (3.8%) 40 (11.9%) 2 (1.5%) 11 (1.6%)
Genotype 4 399 (62.5%) 41 (57.7%) 108 (32.1%) 92 (69.2%) 392 (58.2%)
Genotype 5 1 (0.3%) 67 (9.9%)
Genotype 6
Genotype 7
Shannon Diversity Index (H) 0.81 0.68 1.29 0.71 1.00
Index relative to total possible diversity 41.5% 35.0% 66.5% 36.6% 51.8%
doi:10.1371/journal.pone.0135281.t005
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were included in the systematic review. These yielded 8 HCV incidence/sero-conversion and
240 HCV prevalence measures.
All 465 citations identified through our search underwent an independent secondary
screening for HCV genotype studies (S3 Fig). A total of 163 records were identified as relevant
or potentially relevant after removing duplicates and screening the titles and abstracts of
remaining records. Out of these, 29 records were eligible for inclusion in this secondary system-
atic review during the full-text screening stage yielding 47 HCV genotype study measures.
HCV incidence overview
Out of all countries being analyzed (Iraq, Jordan, Lebanon, Palestine, and Syria), data on HCV
incidence was only available for Iraq and Jordan. There were no studies reporting strictly HCV
incidence rate per person-year. All eight identified incidence measures were based on risk of
sero-conversion over a specified time frame (Table 1). One study conducted across all dialysis
units in Jordan reported a sero-conversion risk of 9.2% over one year [39]. The rest of the stud-
ies were conducted in Iraq. In one study among hemodialysis patients, a sero-conversion risk
of 40.3% over one year was reported [40]. Lower HCV sero-conversion risks ranging from
0–3.5% were observed among pediatric cancer patients [41–43]. A study among newborns to
HCV infected mothers reported 100% clearance of maternal antibodies by six months of age
[44].
HCV prevalence overview
We present here an overview of HCV prevalence studies identified in Iraq, Jordan, Lebanon,
Palestine, and Syria. For the purpose of this analysis, we excluded HCV prevalence studies that
were based on samples of less than 50 participants (37 studies). Accordingly, we report on a
total of 203 HCV prevalence studies including 125 studies from Iraq, 15 from Jordan, 27 from
Lebanon, 17 from Palestine, and 19 from Syria.
Iraq. Among populations at high risk (Table 2), high HCV prevalence levels ranging from
4% to 67.3% were reported among thalassemic patients, with the highest prevalence being
observed among the 2 to 10 year-olds [45]. High HCV prevalence levels were also found
among hemodialysis patients (range: 0–42.6%) [46–55] and hemophilia patients (range: 6.7–
40%) [56–58].
For the general population (Table 3), HCV prevalence varied between 0% and 5.1%, and
ranged between 0% and 2.8% among blood donors, 0% and 5.1% among pregnant women, and
was 0.4% in a national household-based survey [59] and overall less than 1% among other gen-
eral population groups.
Among populations at intermediate risk (S2 Table), HCV prevalence ranged from 0% to
3.3% among health care workers [46, 50, 60–64], and was higher among dental providers
(9.1%) [65], hospitalized patients (14%) [66], and type I diabetes mellitus patients (35.1%) [67].
HCV prevalence also varied widely among special clinical populations ranging from 0%
among patients with malignancies or liver-related problems to 71.9% among acute viral hepati-
tis patients (S2 Table).
Jordan. Among populations at high risk (Table 2), high HCV prevalence levels ranging
from 21% to 49.8% were observed among hemodialysis patients. A prevalence of 32.8% was
also observed among thalassemic patients [68].
For the general population (Table 3), low HCV prevalence levels of less than 1% were
observed among blood donors and people attending health centers (range: 0.1–0.9%). Among
populations at intermediate risk and special clinical populations (S2 Table), low HCV
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prevalence of 0.6% was reported among health care workers [69] and high prevalence of 40.5%
was reported among patients with hemolytic anemia [70].
Lebanon. Among populations at high risk (Table 2), high HCV prevalence of 52.8% was
reported among PWID [71]. Overall high HCV prevalence was also reported among other
populations at high risk (Table 2) such as hemodialysis patients (16% [72] and 27% [73]), thal-
assemia patients (0% [74] and 14% [75]), and multi-transfused cancer patients (4.6% [76]).
For the general population (Table 3), HCV prevalence was measured at less than 0.6%
among Lebanese nationals [73, 76–84] and at about 3% among non-Lebanese nationals resid-
ing in Lebanon [83, 84].
Rather low HCV prevalence was observed among populations at intermediate risk ranging
from 0% among female sex workers and men who have sex with men to 7.7% among HIV
patients infected apparently via the sexual route (S2 Table). Among special clinical populations
(S2 Table), HCV prevalence was 19.6% [85] among hepatocellular carcinoma patients and 0%
[82, 86] among patients with other malignancies.
Palestine. Among populations at high risk (Table 2), HCV prevalence was measured at
27.4% among hemodialysis patients in the West Bank [87], and at 17.9% among hemodialysis
patients in the Gaza strip [88]. A prevalence of 45.2% was reported among PWID in East Jeru-
salem [89].
For the general population (Table 3), HCV prevalence among blood donors from different
parts of Palestine ranged between 0.2% and 0.3% [18, 32–38]. In older studies, all of which
were in the Gaza strip, HCV prevalence was reported at 2.2% and 3.9% among blood donors
[90, 91] and at 9% among outpatient hospital attendees [90].
Syria. Among populations at high risk (Table 2), high HCV prevalence ranging from
48.9% to 75% was reported among hemodialysis patients [92–94]. Meanwhile, HCV prevalence
among drug users (injecting and non-injecting) and among hemophilia patients was measured
at 21% [95] and 20.5% [96], respectively.
For the general population (Table 3), HCV prevalence ranged between 0.3% and 0.9%
among blood donors. Among populations at intermediate risk (S2 Table), HCV prevalence
ranged between 2% among female sex workers [97] and up to 3.8% among health care workers
[98]. The only study among special clinical populations (S2 Table) was among acute viral hepa-
titis patients and reported a prevalence of 1.0% [99].
Overall HCV prevalence ranges and medians. For all countries, HCV prevalence ranged
from 0–75% among populations at high risk with a median of 25.0%, from 0–9% among popu-
lations at low risk with a median of 0.4%, from 0–35.1% among populations at intermediate
risk with a median of 1.2%, and from 0–71.9% among special clinical populations with a
median of 3.4%.
Pooled mean HCV prevalence estimates
Our pooled country-specific estimates for the national population-level HCV prevalence,
based on pooling the general population measures, were: 0.2% (95% CI: 0.1–0.3%) in Iraq,
0.3% (95% CI: 0.1–0.5%) in Jordan, 0.2% (95% CI: 0.1–0.3%) in Lebanon, 0.2% (95% CI: 0.2–
0.3%) in Palestine, 0.4% (95% CI: 0.4–0.5%) in Syria, and 0.2% (95% CI: 0.2–0.3%) in FC coun-
tries as a whole (Table 4). The prediction interval for each of these pooled means, that is the
estimated 95% interval range for the true effect size (HCV prevalence) across studies, also
rarely exceeded 1% (Table 4). The forest plots of the country-specific meta-analyses can be
found in S7–S9 Figs.
High pooled HCV prevalence levels were estimated for populations at high risk: 19.5% (95%
CI: 14.9–24.5%) in Iraq, 37.0% (95% CI: 29.3–45.0%) in Jordan, 14.5% (95% CI: 5.6–26.5%) in
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Lebanon, 47.4% (95% CI: 32.5–62.5%) in Syria, and 23.6% (95% CI: 19.8–27.5%) in FC coun-
tries as a whole (Table 4). The prediction intervals for these measures were also wide across
countries (Table 4).
For populations at intermediate risk, the pooled HCV prevalence was 1.5% (95% CI: 0.7–
2.5%) in Iraq, 1.2% (95% CI: 0.1–3.3%) in Lebanon, and 1.5% (95% CI: 0.9–2.3%) in FC coun-
tries as a whole (Table 4). For special clinical populations, the pooled HCV prevalence was
5.0% (95% CI: 3.4–6.9%) in Iraq and 5.4% (95% CI: 3.7–7.4%) in FC countries as a whole
(Table 4). The prediction intervals for these measures were also wide across countries
(Table 4).
There was significant evidence for heterogeneity in effect size in all meta-analyses, the p-
value was always<0.001 (Table 4). Most of the variation in all meta-analyses was attributed to
variation in effect size across studies rather than chance (I2>60%; Table 4).
HCV RNA prevalence
Our search identified a total of 34 HCV RNA measures (S3 Table). Generally high HCV RNA
prevalence was found among HCV antibody positive individuals at high risk across all coun-
tries ranging from 26.1% among hemodialysis patients to 88% among thalassemia patients.
HCV RNA prevalence was also substantial among HCV antibody negative individuals at high
risk ranging from 3.5% among hemodialysis patients to 16.7% among thalassemic children.
For the general population (S3 Table), the prevalence of HCV RNA among HCV antibody
positive individuals in Iraq and Palestine hovered around 65% in different samples of blood
donors [90, 100, 101], pregnant women [102], and outpatients [90], but was at 89.7% among
blood donors in Jordan [103].
HCV genotypes
Information on HCV genotypes was available in 47 studies including a total of 1749 HCV
RNA positive individuals (Table 5 and S6 Fig).
In Iraq, the majority of participants were infected by a single strain, only 11.3% had multiple
genotypes isolated from their plasma (S6A Fig) [45, 48, 101, 102, 104–110]. The distribution of
HCV genotypes showed a high prevalence for genotype 4 (62.5%) and genotype 1 (33.2%) fol-
lowed by genotype 3 (3.8%) and genotype 2 (0.5%) (Table 5). Subtypes 1a and 1b were isolated,
respectively, from 33.2% and 66.8% of infected persons with genotype 1 (where subtype infor-
mation was available). About two-third of the infections among populations at high risk and
slightly more than half of those among general populations were attributed to genotype 4.
All HCV RNA positive individuals in Jordan were infected by a single strain (S6B Fig), with
57.7% carrying genotype 4 and 42.3% carrying genotype 1 (Table 5) [68, 103, 111, 112]. Sub-
types 1a and 1b were isolated, respectively, from 54.5% and 45.5% of infected persons with
genotype 1. The majority of genotype 1 samples were among hemodialysis and thalassemia
patients, while samples with genotype 4 were equally distributed between populations at high
risk and the general population.
In Lebanon, over 90% of participants were infected by a single strain (S6C Fig) [71, 72, 75,
76, 113–117]. The distribution of genotypes indicated genotype 1 as the most common
(39.9%), followed by genotype 4 (32.1%), genotype 2 (15.8%), genotype 3 (11.9%) and genotype
5 (0.3%) (Table 5). Studies reporting subtype information for genotype 1 showed an equal dis-
tribution of subtypes 1a and 1b. About half of genotype 3 infections (47.5%) were collected
among PWID; and an additional third were collected among hemodialysis and thalassemia
patients. Genotype 3 was also identified in a prison setting [113]. Genotype 5 was reported in
only one study among a sample of patients with symptomatic liver disease [116].
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All HCV genotype studies in Palestine were conducted in the Gaza strip [90, 118]. Almost
all infections were single strained (S6D Fig). Genotype 4 was the most common (69.2%), fol-
lowed by genotype 1 (28.6%), genotype 3 (1.5%) and genotype 2 (0.8%) (Table 5). Subtypes 1a
and 1b constituted, respectively, 69.0% and 31.0% of genotype 1 cases.
The distribution of HCV genotypes in Syria (S6E Fig) revealed genotype 4 as the most com-
mon (58.2%) followed by genotype 1 (29.5%), genotype 5 (9.9%), genotype 3 (1.6%) and geno-
type 2 (0.7%) (Table 5) [92, 119, 120]. Subtypes 1a and 1b were isolated, respectively, from
44.4% and 55.6% of infected persons with genotype 1.
The largest possible value for the Shannon Diversity Index, assuming equal distribution of
the seven known HCV genotypes [121], is 1.95 [29]. Lebanon scored highest on this index
(H = 1.29 out of 1.95 or 66.5%) indicating high diversity in the types and frequency of isolated
genotypes (Table 5). The next most diverse genotype distributions were found in Syria
(H = 1.00 out of 1.95 or 51.8%), and Iraq (H = 0.81 out of 1.95 or 41.5%), while the least diver-
sity was observed in Palestine, more specifically in the Gaza strip (H = 0.71 out of 1.95 or
36.6%), and Jordan (H = 0.68 out of 1.95 or 35.0%).
Risk factors for HCV infection
Few studies (n = 5) investigated possible risk factors for HCV infection using multivariable
logistic regression analyses. Common reported risk factors among hemodialysis patients
included duration of dialysis and number of blood units transfused [54, 94]. Among individu-
als presenting to laboratory units for diverse testing in Lebanon, hemodialysis was the main
risk factor for HCV infection [84]. Meanwhile, maternal age and number of previous miscar-
riages were identified as the main risk factors for HCV infection among pregnant women in
Iraq [102]. Among patients suspected of having acute viral hepatitis, blood transfusion, tattoo-
ing, and cupping were identified as risk factors for HCV infection in a study in Iraq [122].
Quality assessment of HCV incidence and prevalence measures
The results of the quality assessment conducted for the HCV incidence and prevalence mea-
sures are summarized in S4 Table. The study-specific quality assessment for each of these mea-
sures is found in S5–S8 Tables.
The majority of HCV incidence studies involved samples of less than 100 patients, and thus
were classified as having low precision. All studies were based on convenience samples selected
from clinical facilities and were characterized by a high response rate. The type and generation
of the biological assays used to ascertain infection were specified in almost all studies, with
more than half relying on the more recent, sensitive and specific 3rd and 4th generation ELISA
tests.
The majority of HCV prevalence measures had high precision (81.3%). The ROB assess-
ment was possible for 184 HCV prevalence measures, while 19 measures were judged to be of
unknown quality as limited description of the samples was available and were excluded from
further analyses. However, all studies with unknown ROB were based on testing among blood
donors reported by ministries of health and blood banks. For the vast majority of measures
(98.4%), HCV ascertainment was based on biological assays. Information about the generation
of the used assay was missing for more than half of the studies. Among studies with informa-
tion on the assay’s generation, 85.2% reported the use of the more sensitive and specific 3rd and
4th generation assays. Most of the studies were drawn using convenience sampling. Half of the
studies had low ROB in the response rate domain, while 3.8% had high ROB. Response rate
information was missing for 46.2% of the measures.
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Overall, HCV incidence and prevalence studies were of reasonable quality, but incidence
studies were of lower precision. Nearly all studies had low ROB in at least one quality domain
(99.0%), and 47.9% of all studies had low ROB in at least two of the three quality domains. Less
than 3.6% of all studies had high ROB in two or three quality domains.
Discussion
We presented to our knowledge the first systematic review and synthesis of HCV incidence
and prevalence across countries of the FC subregion of MENA. We also provided estimates for
HCV prevalence at the national level and for various at risk populations. Our results suggest
that HCV prevalence is at less than 1% among the general population across these countries
(Table 4). Meanwhile, high prevalence levels were noted among hemodialysis, thalassemia and
multi-transfused patients (Table 2). Genotypes 4 and 1 seem to be the most common genotypes
circulating in these countries (Table 5 and S6 Fig).
Our estimates for the national HCV prevalence of less than 1% suggest that HCV levels in
these countries are comparable to those in developed and other developing countries, but are
towards the lower end of the global range [1, 2, 123]. These estimates also suggest that this sub-
region appears to have the lowest HCV prevalence of all MENA subregions [7, 11–15]—sub-
stantially lower than in other MENA countries namely Egypt [6, 7] and Pakistan [8, 9].
A large fraction of HCV prevalence measures in the general population were among blood
donors, and HCV prevalence in this normally healthy population may underestimate HCV
prevalence in the population at large. In the USA, for example, HCV prevalence among blood
donors [124] is substantially lower than that estimated in nationally-representative popula-
tion-based surveys [125]. We conducted sensitivity analyses (not shown) to examine the
impact of excluding blood donor data on our pooled estimates for HCV prevalence. For Iraq,
HCV prevalence increased substantially from 0.2% to 0.8% with the exclusion of blood donors.
Meanwhile, there were minor changes to the prevalence in Jordan (0.3% versus 0.2%) and Leb-
anon (0.2% versus 0.3%). Sensitivity analyses were not possible for Palestine and Syria due to
the small number of studies among other general population groups (1 study in Palestine and 0
studies in Syria).
Overall, these results support our conclusion that HCV prevalence is likely to be below 1%
among the population at large in each of the FC countries. It bears notice that our estimate for
HCV prevalence in Iraq is substantially lower than that estimated recently using a different
methodology in a global study (0.2% in our study versus 3.2% in Gower et al. study [22]). The
difference in estimates arises from Gower et al. [22] basing their estimate on a single study
[102] while our pooled prevalence was based on 99 studies, a large fraction of which were iden-
tified through our expanded search of data in non-indexed journals.
Despite the lower prevalence among the population at large, our findings indicate on-going
transmission in at least some medical facilities. Exposures to hemodialysis [54, 84, 94] or blood
transfusion [54, 122] were cited as risk factors for acquiring HCV. High HCV prevalence was
generally observed among hemodialysis and thalassemia patients across countries (Table 2).
High sero-conversion risks of up to 40% were found among hemodialysis patients in prospec-
tive studies (Table 1). Measurable HCV RNA prevalence among HCV antibody negative
clinical populations were documented suggesting recent nosocomial HCV exposures (S3
Table). Higher HCV levels (compared to the general population) among health care workers,
hospitalized populations, different clinical populations, diabetics, and dental providers were
identified suggesting health care related HCV exposures (S2 Table). While some of the preva-
lent HCV exposures may date to times before the enforcement of more stringent blood screen-
ing and infection control protocols in these countries, the totality of the evidence supports the
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conclusion of ongoing transmission in some clinical settings and through medical procedures.
These results emphasize the importance of reinforcing blood screening and infection control in
health care facilities.
Other HCV risk factors identified in this review included exposure to infected needles and
sharp objects during tattooing and cupping procedures [122]. The latter, also known as hijama,
is a common practice by community healers in MENA [18, 126]. There is also evidence else-
where in MENA of a wider scope of community related HCV exposures as well as traditions of
some professions, such as barbers, administering health care related procedures such as injec-
tions [7, 18, 127]. These findings highlight the relevance of controlling these exposures and
insuring the safety of injections. This could be done, for example, by wide-scale replacement of
current re-usable syringes with safety-engineered “smart” syringes [128, 129].
The ongoing political and military conflicts in this subregion (Iraq, Palestine, and Syria)
introduce more challenges and serious barriers to the implementation of stringent blood
screening and infection control in medical facilities and in communities. Shortages of medical
supplies and trained human capital in these countries are often exacerbated by intermittent
electricity and water supplies making the provision of even basic medical care difficult [42,
130–132]. Implications of these emergencies on current HCV transmission are unknown.
Injecting drug use appears to be the dominant driver of HCV incidence in many developed
countries [133–135]. The estimated population proportion of injecting drug use among the
adult population in FC ranges between 0.07% in Syria and 0.35% in Palestine [136]. The popu-
lation proportion of injecting drug use in MENA as a whole is estimated at 0.24%; in the inter-
mediate range compared to global levels [136]. Our search identified only few studies assessing
the status of HCV infection among PWID and other drug users [18, 71, 89]. These showed
HCV prevalence varying between 21% in Syria and 52.8% in Lebanon (Table 2). Relatively low
HCV prevalence has been observed among prisoners, a fraction of whom are often drug users,
in Iraq (0.6%) [137] and in Lebanon (3.4%) [113]. HCV prevalence among PWID in FC seems
thus somewhat lower than that observed in other MENA countries and globally [23, 136].
With these overall limited data on HCV among PWID, it is difficult to judge the relative
importance of injecting drug use as a driver of HCV incidence and prevalence in FC.
Migration dynamics within MENAmay have played a role in HCV epidemiology in this
subregion. This is specially so in relation to the epidemic in Egypt, the country with the largest
HCV prevalence worldwide [6, 7]. The epidemic in Egypt is almost exclusively dominated by
genotype 4 (>90%) [138], which is also a highly prevalent genotype in FC (Table 5). Genotype
4 in MENA appears to have a larger frequency in countries geographically close to Egypt and/
or in countries that host or have hosted large migrant labor populations from Egypt [11, 12].
Iraq in particular, but also Jordan and Lebanon, have hosted or are currently hosting millions
of Egyptian migrant labor [139–142]. A large fraction of the labor market in Iraq at some point
consisted of Egyptian migrant workers who formed the backbone of the major infrastructure
and developmental projects and agricultural sector in this country—such as during the era of
the Iraq-Iran war [139–141]. Movement of Egyptian labor, who often came from rural areas
most affected by HCV [7], may have contributed to higher circulation of genotype 4 in host
countries, but has had a limited impact on HCV prevalence in these countries. FC countries
appear to have some of the lowest HCV prevalence levels globally.
The Gaza strip, which borders Egypt, seems to be the part of FC most influenced by HCV
dynamics in Egypt. The Gaza strip was under Egyptian rule prior to the 1967 Israeli occupation
and shares strong historical, cultural, and economic ties with Egypt. With the protracted Israeli
siege of Gaza, Egypt has become the main gateway for Gaza residents to the world and the
country that provides essential services to the people of Gaza. Gazans often seek medical treat-
ment in Egypt for conditions that cannot be treated in this largely impoverished district. It is
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probably not surprising therefore that genotype 4 appears to be the dominant genotype in
Gaza, and specially so among those with a history of travel, or of receiving medical care, includ-
ing blood transfusions or surgical operations, in Egypt [118].
A substantial fraction of genotype 3 infections in FC were observed among PWID, affirming
a global link between this genotype and injecting drug use [121, 138, 143]. Apart from Leba-
non, very limited number of genotype 3 infections were identified (Table 5). One reason could
be that PWID contribution to HCV incidence is not large in these countries, and/or that geno-
types 4 and 1 are the dominant genotypes circulating among PWID. An alternative explana-
tion, and possibly a more plausible one, is that existing studies of genotypes have not yet
reached this largely hidden population whose contribution to HCV incidence and prevalence
remains poorly understood.
Lebanon and Syria showed higher genotype diversity with genotype 5 only detected in these
countries, and genotype 2 being more prevalent in Lebanon than in the rest of FC (Table 5).
These findings are consistent with the large scale emigration rates and diaspora populations of
these two countries globally—specifically so for Lebanon. Such population movements may
provide avenues for genotypes that are prevalent in other parts of the world, say in West Africa
and Latin America for genotype 2 [121, 141] and South Africa for genotype 5 [121, 138], to be
introduced into circulation in some of these countries.
Our systematic review and meta-analyses are limited by the variability in quantity and qual-
ity of studies across countries. There were few studies that assessed HCV incidence and some
countries did not have sufficient number of prevalence measures in some of the at risk popula-
tions to warrant conduct of meta-analyses. With the convenience sampling in most studies,
and the country-specific variability in frequency, specific population and geographical location
of available data, the estimates may not be representative of the true HCV population preva-
lence. Data was also limited for some of the specific populations that play an important role in
HCV epidemiology, most notably PWID. HCV RNAmeasures were limited in quantity and
were often based on relatively small samples.
The number of genotyped infections was not large in all countries and available genotype
data may not have captured the diversity and true frequency of genotypes across the different
at risk populations in each country. For example, there were some differences, though minor,
between the genotype frequencies identified here compared to those of two recent studies of
global genotype distribution [22, 121]. The main source of differences appears to be the inclu-
sion of more studies on HCV genotypes in our review, largely as a consequence of including
regional and national databases in our search of non-indexed published literature (S3 and S6
Figs).
Our meta-analyses highlighted heterogeneity in effect size among included studies. This is
not unexpected considering the differences in prevalence measures in terms of the specific pop-
ulation studied, sampling methodology and participant recruitment, age-group representation
in the sample, year of study, location and assay used [12]. However, due to the relatively small
number of outcome measures for each country, we were unable to conduct a meaningful multi-
variable meta-regression analysis to identify sources of heterogeneity in effect size.
Conclusions
HCV prevalence in the population at large in FC appears to be below 1%, and is tending
towards the lower end of the global range. HCV prevalence among high risk populations, such
as hemodialysis and thalassemia patients, is considerable and the evidence indicates ongoing
HCV transmission in at least some medical facilities. Genotypes 4 and 1 appear to be the most
prevalent, and genotype distributions suggest a role for recent migrations in the circulation of
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different genotypes across national borders. With the limitations in available data, infection
levels among PWID and the contribution of this population to HCV incidence and prevalence
remain uncertain. The implications of the ongoing military conflicts and ensuing emergencies
in FC on current HCV transmission are unknown.
Further research is needed for a better understanding of the epidemiology of this infection
in this MENA subregion. Elucidation of the role of key populations in HCV transmission, such
as PWID, is needed. Conduct of nationally-representative population-based surveys to esti-
mate HCV prevalence, delineate spatial variability in prevalence, identify modes of exposure,
and assess HCV knowledge and attitudes, as has been done recently in Egypt [6, 144–148], will
enhance our knowledge of the epidemiology of this infection in this part of the world.
Our findings inform planning of health service provision, articulation of HCV policy guide-
lines, and implementation of effective HCV programming to reduce HCV transmission and
decrease the burden of its associated diseases. Since HCV exposures in FC are linked to specific
settings, HCV prevention efforts should be targeted and focus on infection control in clinical
settings and harm reduction among PWID. Adoption of the newWorld Health Organization
guidelines for the use of safety-engineered syringes [128, 129] can also minimize exposure to
HCV and other blood-borne pathogens.
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